首页> 外文期刊>Journal of travel medicine. >Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration.
【24h】

Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration.

机译:病毒体甲型肝炎疫苗:将皮内和皮下与肌内给药进行比较。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Vaccination against hepatitis A virus (HAV) is unaffordable to many developing countries. Substantial reductions in cost occur when vaccines are administered intradermally at low doses. Aluminum-free HAV vaccines are considered more suitable for intradermal use than traditional vaccines which can cause long-lasting local reactions. Thus, we compared the immunogenicity and safety of an aluminum-free virosomal HAV vaccine (Epaxal) administered by different routes: intradermal (i.d.), subcutaneous (s.c.), and intramuscular (i.m.). METHODS: Two open pilot studies were conducted as sub-studies of a large lot consistency trial. Healthy subjects aged 18 to 45 were enrolled. Study 1 compared two i.d. regimens of a lower dose of Epaxal [0.1 mL (4.8 IU), one or two injection sites] with i.m. administration of the standard dose [0.5 mL (24 IU)]. Study 2 compared the s.c. with the i.m. administration of the standard dose. At month 12, subjects in study 1 received a booster dose of 0.1 mL i.d. or 0.5 mL i.m.; subjects in study 2 received 0.5 mL via the respective route (s.c. or i.m.). Serum was tested for antibodies at baseline, 2 weeks (study 1), and 1 and 6 months after the primary vaccination as well as prior and 1 month after the booster dose. Incidences of solicited and unsolicited adverse events were recorded. RESULTS: Seroprotection rates (anti-HAV geometric mean concentration of > or =20 mIU/mL) after 1 month ranged from 93.2% to 100% in all groups and remained high until month 12 (range 85.2&-90.2%). Complete (100%) seroprotection was achieved by all subjects in all groups after booster vaccination. All routes of administration were well tolerated. Local reactions were more common in subjects vaccinated i.d. and s.c. than i.m. CONCLUSIONS: The aluminum-free virosomal HAV vaccine Epaxal is highly immunogenic and well tolerated when administered either via i.d., s.c., or i.m. Vaccination via the i.d. route may confer significant cost savings over the conventional i.m. route.
机译:背景:对许多发展中国家的病毒(HAV)疫苗接种疫苗接种病毒(HAV)。当疫苗以低剂量施用疫苗时,成本的实质性降低。无铝的HAV疫苗被认为比传统疫苗更适合于皮内使用,这可能导致持久的局部反应。因此,我们将通过不同途径给药的无铝毒蕈瘤HAV疫苗(锁定)的免疫原性和安全性进行了比较:皮内(I.D.),皮下(S.C.)和肌肉内(即)。方法:两项开放试验研究是对大量一致性试验的副研究。注册了18至45岁的健康科目。研究1比较了两个I.D. I.M.施用标准剂量[0.5ml(24 IU)]。研究2比较S.C.有了我。管理标准剂量。在12月12日,研究中的受试者1获得了0.1毫升的增强剂量。或0.5 ml i.m .;研究中的受试者2通过各自的路线(S.C.或I.M.)收到0.5毫升。在基线的抗体测试血清,2周(研究1)和初级疫苗接种后1和6个月,以及在增强剂量后的先前和1个月。记录了征集和未经请求的不良事件的发病率。结果:1个月后1个月后的SeroProction率(抗HAV几何平均浓度>或= 20 mIU / ml)在所有基团中的93.2%至100%,直到一个月12(范围为85.2&-90.2%)。完全(100%)在加强疫苗接种后的所有群体中的所有受试者都能实现。所有给药途径都耐受良好。在疫苗接种的受试者中,局部反应更常见。和S.C.比是的。结论:当通过I.D.,S.C.或i..M.施用时,无铝毒蕈粉疫苗暂象是高度免疫原性和耐受性的。通过I.D的疫苗接种。路线可能会在传统的i.M上赋予显着的成本节省。路线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号